- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ISR IMMUNE SYSTEM REGULATION Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 11,180 | +3,61 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,271 | -2,22 % | PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications | ||
| CENTOGENE | 0,132 | +1,54 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 3,010 | -1,05 % | This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday | ||
| BIOMERIEUX | 125,40 | +0,40 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| CYCLACEL | 11,562 | -11,31 % | Cyclacel Pharmaceuticals, Inc. - 8-K, Current Report | ||
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| GENUS | 28,600 | +0,70 % | Genus: Underlying Group Trading In-line With Expectations | LONDON (dpa-AFX) - Genus (GNS.L) issued trading update for fiscal year ended 30 June 2025. The Group said it recorded strong underlying Group trading in-line with expectations. As a result of... ► Artikel lesen | |
| ABIONYX PHARMA | 1,812 | +25,83 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX)
Market:... ► Artikel lesen | |
| ANAPTYSBIO | 20,800 | -5,45 % | Analyst Expectations For AnaptysBio's Future | ||
| XTL BIOPHARMACEUTICALS | 1,350 | -2,17 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| AKESO | 16,900 | -0,59 % | Akeso, Inc.: NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer | HONG KONG, July 28, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration... ► Artikel lesen | |
| MEIRAGTX | 7,000 | +1,45 % | MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease | - This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the benefits... ► Artikel lesen | |
| MAAT PHARMA | 5,440 | +5,02 % | MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology | Tranche-based financing to support clinical development for the Company's late-stage assets in hemato-oncology including Xervyteg currently under review for potential approval by the EMA and MaaT033... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,069 | -0,58 % | Isofol Medical AB: Isofol successfully completes pre-IND meeting with the FDA for arfolitixorin | GOTHENBURG, Sweden, July 16, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed a pre-IND meeting with the U.S. Food and Drug Administration... ► Artikel lesen |
ISR IMMUNE SYSTEM REGULATION HOLDING AB gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISR IMMUNE SYSTEM REGULATION HOLDING AB finden Sie auf Wallstreet Online.